Clinical Trial Update: Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) [Phase 2]

View source ↗

Summary

Phase 2 trial update for AKCEA-ANGPTL3-LRx (ISIS 703802) in Familial Chylomicronemia Syndrome (and related lipoprotein lipase deficiency) has completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome
• Hyperlipoproteinemia Type 1
• Lipoprotein Lipase Deficiency

Drugs mentioned

• AKCEA-ANGPTL3-LRx (ISIS 703802) (AKCEA-ANGPTL3-LRx)

Snippet

Sponsor: Akcea Therapeutics | Conditions: Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2021-01-07